RecruitingPhase 1NCT07103018
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Sponsor: K36 Therapeutics, Inc.
Durham, NC · +12 more sites
Prostate Cancer clinical trials in Durham, NC
31 recruiting prostate cancer studies with a site in Durham, NC.
RecruitingPhase 1 / Phase 2NCT07226986
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Sponsor: Novartis Pharmaceuticals
Durham, NC · +3 more sites
RecruitingPhase 3NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Sponsor: Pfizer
Cary, NC · Durham, NC · +124 more sites
RecruitingPhase 1 / Phase 2NCT07206056
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Sponsor: Novartis Pharmaceuticals
Durham, NC · +7 more sites
RecruitingPhase 1 / Phase 2NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Sponsor: Parabilis Medicines, Inc.
Durham, NC · +30 more sites
RecruitingNot applicableNCT06995898
The Vanguard Study: Testing a New Way to Screen for Cancer
Sponsor: National Cancer Institute (NCI)
Chapel Hill, NC · Durham, NC · +43 more sites
RecruitingPhase 1 / Phase 2NCT04585750
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Sponsor: PMV Pharmaceuticals, Inc
Durham, NC · +31 more sites
RecruitingPhase not listedNCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Sponsor: Alliance for Clinical Trials in Oncology
Asheville, NC · Cary, NC · Clinton, NC · +744 more sites
RecruitingPhase 1NCT05176483
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Sponsor: Exelixis
Durham, NC · +45 more sites
RecruitingPhase 1 / Phase 2NCT06800313
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Durham, NC · +16 more sites
RecruitingPhase not listedNCT07124000
DESTINY-PANTUMOUR04
Sponsor: AstraZeneca
Durham, NC · Wilson, NC · +16 more sites
RecruitingPhase 3NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Durham, NC · +58 more sites
RecruitingPhase 2NCT04038502
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Sponsor: VA Office of Research and Development
Durham, NC · +17 more sites
RecruitingPhase 2NCT05011383
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Sponsor: VA Office of Research and Development
Durham, NC · Salisbury, NC · +15 more sites
RecruitingPhase 1NCT07493512
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Sponsor: Amgen
Durham, NC · +11 more sites
RecruitingPhase 3NCT06056830
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Sponsor: Clarity Pharmaceuticals Ltd
Durham, NC · +28 more sites
RecruitingNot applicableNCT06830265
Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis
Sponsor: Uro-1 Medical
Durham, NC · +2 more sites
RecruitingPhase 2NCT06022822
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
Sponsor: National Cancer Institute (NCI)
Durham, NC · +4 more sites
RecruitingPhase 1NCT04221542
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Amgen
Durham, NC · Winston-Salem, NC · +23 more sites
RecruitingPhase 1 / Phase 2NCT06785636
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Sponsor: Pathos AI, Inc.
Durham, NC · +18 more sites
RecruitingPhase 2NCT06842498
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor: Kyntra Bio
Durham, NC · +22 more sites
RecruitingPhase 2NCT05832086
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Sponsor: Stephen Freedland
Durham, NC · +2 more sites
RecruitingPhase 1NCT06067841
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Sponsor: Bristol-Myers Squibb
Durham, NC · +7 more sites
RecruitingPhase 1 / Phase 2NCT05652686
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Sponsor: Phanes Therapeutics
Chapel Hill, NC · Durham, NC · +13 more sites
RecruitingPhase 1 / Phase 2NCT06457919
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Durham, NC · +11 more sites
RecruitingPhase not listedNCT03151629
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Sponsor: Prostate Cancer Clinical Trials Consortium
Chapel Hill, NC · Durham, NC · +45 more sites
RecruitingPhase 2 / Phase 3NCT04787744
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Sponsor: VA Office of Research and Development
Durham, NC · +19 more sites
RecruitingNot applicableNCT06555588
Engage Psychosocial Intervention for Cancer Symptoms
Sponsor: Duke University
Durham, NC
RecruitingPhase 1NCT06778863
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Sponsor: Clasp Therapeutics, Inc.
Durham, NC · +20 more sites
RecruitingPhase not listedNCT06141993
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Sponsor: Duke University
Durham, NC · +2 more sites
Not yet recruitingNot applicableNCT07685249
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Sponsor: Duke University
Durham, NC
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.